FrancophonIA/ELRC3.0 huggingface dataset:
English: One vial of 5 ml contains 37.5 mg of atosiban (as acetate).
Croatian: Jedna bočica od 5 ml otopine sadrži 37,5 mg atosibana (u obliku atosibanacetata).
English: - if you or your unborn baby have any other conditions where it would be dangerous to continue with your pregnancy.
Croatian: - ako se placenta odvaja od stijenke maternice. - ako Vi ili fetus imate bolesti zbog kojih se nastavak Vaše trudnoće smatra izrazito rizičnim.
English: What Tractocile looks like and contents of the pack Tractocile 6.75 mg/0.9 ml solution for injection is a clear, colourless solution without particles.
Croatian: Tractocile 6,75 mg/0,9 ml otopina za injekciju je prozirna, bezbojna otopina bez čestica.
English: One vial of 0.9 ml contains 6.75 mg of atosiban (as acetate).
Croatian: Jedna bočica od 0,9 ml sadrži 6,75 mg atosibana (u obliku atosibanacetata)
English: - if your unborn baby is small for the time of your pregnancy.
Croatian: - ako je nerođeno dijete premalo u odnosu na trajanje trudnoće. - nakon poroda mogla bi se smanjiti sposobnost kontrakcije
English: Each vial of 0.9 ml solution contains 6.75 mg atosiban (as acetate).
Croatian: Jedna bočica od 0,9 ml otopine sadrži 6,75 mg atosibana (u obliku atosibanacetata).
English: If you get any side effects, talk to your doctor, midwife or pharmacist.
Croatian: Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika, babicu ili ljekarnika.
English: During treatment with Tractocile, your contractions and your unborn baby's heart rate may be monitored.
Croatian: Kontrakcije maternice i brzina otkucaja srca nerođenog djeteta trebaju se nadzirati za vrijeme liječenja lijekom Tractocile.
English: Further treatment cycles of Tractocile can be used should contractions recur.
Croatian: Ako se kontrakcije ponovno pojave, mogu se primijeniti dodatni ciklusi liječenja lijekom Tractocile.
English: CARTON
Croatian: Tahikardia
English: Common (affects less than 1 in 10 people) - headache - feeling dizzy - hot flushes - being sick (vomiting) - fast heartbeat - Low blood pressure.
Croatian: Često (pojavljuje se u manje od 1 na 10 osoba) - glavobolja. - omaglica. - navale vrućine.
English: Tractocile 6.75 mg/0.9 ml injection atosiban
Croatian: Tractocile 6,75 mg/0,9 ml otopina za injekciju atosiban
English: Nausea Vomiting
Croatian: - povraćanje.
English: 0.9 ml (6.75 mg /0.9 ml)
Croatian: SADRŽAJ PO TEŽINI, VOLUMENU ILI BROJU JEDINICA LIJEKA 0,9 ml (6,75 mg /0,9 ml)
English: Preparation of the intravenous infusion solution:
Croatian: Priprema otopine za infuziju u venu:
English: Tractocile 37.5 mg/5 ml sterile concentrate atosiban
Croatian: Tractocile 37.5 mg/5 ml sterilni koncentrat atosiban i.v.
English: Tractocile 37.5 mg/5 ml concentrate for solution for infusion Atosiban
Croatian: Tractocile 37,5 mg/5 ml koncentrat za otopinu za infuziju atosiban
English: Tractocile 37.5 mg/5 ml concentrate for solution for infusion
Croatian: Tractocile 37,5 mg/5 ml koncentrat za otopinu za infuziju
English: Tractocile 6.75 mg/0.9 ml solution for injection
Croatian: Tractocile 6,75 mg/0,9 ml otopina za injekciju
English: It also makes the contractions happen less often.
Croatian: Također, smanjuje i učestalost kontrakcija maternice.
English: 5 ml (7.5 mg/ml)
Croatian: SADRŽAJ PO TEŽINI, VOLUMENU ILI BROJU JEDINICA LIJEKA 5 ml (7,5 mg/ml)
English: Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder:
Croatian: Nositelj odobrenja za stavljanje lijeka u promet i proizvođač Nositelj odobrenja za stavljanje u promet gotovog lijeka: Ferring Pharmaceuticals A/S
English: Pruritis, Rash
Croatian: Svrbež, Osip
English: United Kingdom Ferring Pharmaceuticals Ltd. Tel: +44 844 931 0050 contact2@ferring.com
Croatian: Tel: +44 844 931 0050 contact2@ferring.com
English: - Each vial of Tractocile 6.75 mg/0.9 ml solution for injection contains atosiban acetate equivalent to
Croatian: Tractocile 6,75 mg/0,9 ml otopine za injekciju sadrži atosibanacetat što odgovara
English: The full EPAR for Palonosetron Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Palonosetron Hospira nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: When 5HT attaches to these receptors, it normally causes nausea and vomiting.
Croatian: Kada se 5HT vezuje na te receptore, obično uzrokuje mučninu i povraćanje.
English: It is available as a solution for injection which should be given by a healthcare professional about 30 minutes before the start of chemotherapy.
Croatian: Dostupan je kao otopina za injekciju koju treba dati zdravstveni djelatnik otprilike 30 minuta prije početka kemoterapije.
English: In adults, the recommended dose is 250 micrograms, injected into a vein over 30 seconds.
Croatian: Preporučena doza u odraslih osoba iznosi 250 mikrograma, a ubrizgava se u venu tijekom 30 sekundi.
English: This means that Palonosetron Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aloxi.
Croatian: To znači da je Palonosetron Hospira sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Aloxi.
English: This means that it stops a chemical in the body called 5-hydroxytryptamine (5HT, also known as serotonin) from attaching to 5HT3 receptors in the gut.
Croatian: To znači da sprječava vezivanje kemikalije prisutne u tijelu koja se naziva 5-hidroksitriptamin (5HT, poznata također pod nazivom serotonin) na receptore 5HT3 u crijevima.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Palonosetron Hospira has been shown to be comparable to Aloxi.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da je u skladu sa zahtjevima EU-a dokazano da je lijek Palonosetron Hospira usporediv s lijekom Aloxi.
English: the solution should be given by infusion (drip) into a vein over 15 minutes at a dose of 20 micrograms per kilogram body weight.
Croatian: U djece otopinu treba primjenjivati infuzijom (dripom) u venu tijekom razdoblja od 15 minuta u dozi od 20 mikrograma po kilogramu tjelesne težine.
English: It is used in adults and children 1 month of age or older for chemotherapy with medicines that are either a strong trigger of nausea and vomiting (such as cisplatin) or a moderate trigger (such as cyclophosphamide, doxorubicin or carboplatin).
Croatian: Primjenjuje se u odraslih osoba i djece u dobi od mjesec dana i starijih za kemoterapiju s lijekovima koji su snažni aktivatori mučnine i povraćanja (poput cisplatina) ili umjereni aktivatori (poput ciklofosfamida, doksorubicina ili karboplatina).
English: This is a summary of the European public assessment report (EPAR) for Palonosetron Hospira.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Palonosetron Hospira.
English: Because Palonosetron Hospira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Palonosetron Hospira generički lijek, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: By blocking these receptors, Palonosetron Hospira prevents the nausea and vomiting that often happen after chemotherapy.
Croatian: Inhibirajući te receptore, Palonosetron Hospira sprječava mučninu i povraćanje koje se često pojavljuje nakon kemoterapije.
English: Palonosetron Hospira is a ‘generic medicine'.
Croatian: Palonosetron Hospira je „generički lijek”.
English: Palonosetron Hospira is used to prevent nausea (feeling sick) and vomiting caused by chemotherapy (medicines to treat cancer).
Croatian: Palonosetron Hospira koristi se za sprječavanje mučnine (osjećaja slabosti) i povraćanja uzrokovanog kemoterapijom (lijekovima koji se koriste za liječenje raka).
English: What measures are being taken to ensure the safe and effective use of Palonosetron Hospira?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Palonosetron Hospira?
English: No additional studies were needed as Palonosetron Hospira is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Aloxi.
Croatian: Nisu bila potrebna dodatna ispitivanja jer je Palonosetron Hospira generički lijek koji se daje injekcijom i sadrži istu djelatnu tvar kao i referentni lijek Aloxi.
English: Palonosetron Hospira should only be given before chemotherapy and can only be obtained with a prescription.
Croatian: Palonosetron Hospira smije se davati samo prije kemoterapije, a dostupan je samo uz liječnički recept.
English: The company provided data from the published literature on palonosetron.
Croatian: Tvrtka je dostavila podatke o palonosetronu iz objavljene literature.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Palonosetron Hospira, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi za lijek Palonosetron Hospira nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Other information about Palonosetron Hospira
Croatian: Ostale informacije o lijeku Palonosetron Hospira
English: What is Palonosetron Hospira and what is it used for?
Croatian: Što je Palonosetron Hospira i za što se koristi?
English: A risk management plan has been developed to ensure that Palonosetron Hospira is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Palonosetron Hospira.
English: What are the benefits and risks of Palonosetron Hospira?
Croatian: Koje su koristi i rizici lijeka Palonosetron Hospira?
English: It is not intended to provide practical advice on how to use Palonosetron Hospira.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Palonosetron Hospira.
English: The Committee recommended that Palonosetron Hospira be approved for use in the EU.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Palonosetron Hospira u EU-u.
English: For more information about treatment with Palonosetron Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Palonosetron Hospira pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: The active substance in Palonosetron Hospira, palonosetron, is a ‘5HT3 antagonist'.
Croatian: Djelatna tvar lijeka Palonosetron Hospira, palonosetron, je „antagonist receptora 5HT3”.
English: Why is Palonosetron Hospira approved?
Croatian: Zašto je Palonosetron Hospira odobren?
English: For practical information about using Palonosetron Hospira, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Palonosetron Hospira pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
English: Therefore, the CHMP's view was that, as for Aloxi, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a kako koristi nadmašuju utvrđeni rizik, kao i kod lijeka Aloxi.
English: It may be given with a corticosteroid (another type of medicine that can be used to prevent nausea and vomiting) to increase the effect.
Croatian: Može se dati s kortikosteroidom (drugom vrstom lijekova koji se mogu
English: Palonosetron Hospira contains the active substance palonosetron.
Croatian: Palonosetron Hospira sadrži djelatnu tvar palonosetron.
English: How is Palonosetron Hospira used?
Croatian: Kako se Palonosetron Hospira koristi?
English: How has Palonosetron Hospira been studied?
Croatian: Kako je Palonosetron Hospira ispitivan?
English: Date of first authorisation: 10 January 2008 Date of latest renewal: 20 September 2012
Croatian: Datum posljednje obnove odobrenja: 20. rujna 2012.
English: STOP taking TESAVEL and contact a doctor immediately if you notice any of the following serious side effects:
Croatian: PRESTANITE uzimati TESAVEL i odmah se javite liječniku ako primijetite bilo koju od sljedećih ozbiljnih nuspojava:
English: Other medicines and TESAVEL
Croatian: Drugi lijekovi i TESAVEL
English: What TESAVEL is and what it is used for
Croatian: Što je TESAVEL i za što se koristi
English: What TESAVEL contains
Croatian: Što TESAVEL sadrži
English: If you take more TESAVEL than you should If you take more than the prescribed dosage of this medicine, contact your doctor immediately.
Croatian: Ako uzmete više lijeka TESAVEL nego što ste trebali Uzmete li veću dozu ovog lijeka od propisane, odmah se javite svom liječniku.
English: Your doctor may ask you to stop TESAVEL.
Croatian: Vaš liječnik može zatražiti da prestanete s uzimanjem lijeka TESAVEL.
English: Due to lack of human data, TESAVEL should not be used during pregnancy.
Croatian: Zbog nedostatka podataka o primjeni u ljudi, TESAVEL se ne smije uzimati tijekom trudnoće.
English: The level of digoxin in your blood may need to be checked if taking with TESAVEL.
Croatian: Možda će biti potrebno provjeravati razinu digoksina u Vašoj krvi ukoliko se uzima s lijekom TESAVEL.
English: - an allergic reaction to TESAVEL (see section 4).
Croatian: - Alergijsku reakciju na lijek TESAVEL (pogledajte dio 4).
English: Do not take TESAVEL - if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).
Croatian: Nemojte uzimati lijek TESAVEL - ako ste alergični na sitagliptin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
English: What TESAVEL is and what it is used for What you need to know before you take TESAVEL How to take TESAVEL
Croatian: Što je TESAVEL i za što se koristi Što morate znati prije nego počnete uzimati lijek TESAVEL
English: What TESAVEL looks like and contents of the pack
Croatian: Kako TESAVEL izgleda i sadržaj pakiranja
English: What you need to know before you take TESAVEL
Croatian: Što morate znati prije nego počnete uzimati lijek TESAVEL
English: The European Medicines Agency has deferred the obligation to submit the results of studies with TESAVEL in one or more subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka TESAVEL u jednoj ili više podskupina pedijatrijske populacije za dijabetes mellitus tipa 2 (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg).
Croatian: Ako imate tegobe s bubrezima, liječnik Vam može propisati niže doze(kao što su 25 mg ili 50 mg).
English: For adult patients with type 2 diabetes mellitus, TESAVEL is indicated to improve glycaemic control:
Croatian: U odraslih bolesnika s dijabetesom mellitus tipa 2, TESAVEL je indiciran za poboljšanje regulacije glikemije:
English: TESAVEL should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Croatian: TESAVEL se ne smije primjenjivati u bolesnika s dijabetesom tipa 1 ili za liječenje dijabetičke ketoacidoze.
English: If pancreatitis is suspected, TESAVEL and other potentially suspect medicinal products should be discontinued; if acute pancreatitis is confirmed, TESAVEL should not be restarted.
Croatian: Posumnja li se na pankreatitis, mora se prekinuti primjena lijeka TESAVEL i drugih lijekova za koje se sumnja da bi ga mogli izazvati; potvrdi li se akutni pankreatitis, liječenje lijekom TESAVEL ne smije se ponovno započeti.
English: Since co-administration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics, TESAVEL may be administered with or without food.
Croatian: Budući da istodobno uzimanje sitagliptina s punomasnim obrokom nema učinka na farmakokinetiku, TESAVEL se može uzimati s hranom ili bez nje.
English: Method of administration TESAVEL can be taken with or without food.
Croatian: Način primjene TESAVEL se može uzimati s hranom ili bez nje.
English: TESAVEL is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
Croatian: TESAVEL je također indiciran kao dodatak inzulinu (sa ili bez metformina) kada dijeta i tjelovježba uz stabilnu dozu inzulina ne omogućuju odgovarajuću regulaciju glikemije.
English: Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of TESAVEL and periodically thereafter.
Croatian: S obzirom da se doza prilagođava temeljem bubrežne funkcije, preporučuje se procijeniti bubrežnu funkciju prije uvođenja lijeka TESAVEL te periodično nakon toga.
English: TESAVEL has not been studied in patients with severe hepatic impairment and care should be exercised (see section 5.2).
Croatian: TESAVEL nije ispitivan u bolesnika s teškim oštećenjem funkcije jetre, te je potreban oprez (vidjeti dio 5.2).
English: TESAVEL has no or negligible influence on the ability to drive and use machines.
Croatian: TESAVEL ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: If you forget to take TESAVEL
Croatian: Ako ste zaboravili uzeti lijek TESAVEL
English: If you stop taking TESAVEL
Croatian: Ako prestanete uzimati lijek TESAVEL
English: When TESAVEL is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see section 4.4).
Croatian: Kada se TESAVEL uzima u kombinaciji sa sulfonilurejom ili inzulinom, može se razmotriti niža doza sulfonilureje ili inzulina kako bi se smanjio rizik od hipoglikemije (vidjeti dio 4.4).
English: In addition, patients should be alerted to the risk of hypoglycaemia when TESAVEL is used in combination with a sulphonylurea or with insulin.
Croatian: Bolesnike se također mora upozoriti na rizik od hipoglikemije kad se TESAVEL uzima u kombinaciji sa sulfonilurejom ili s inzulinom.
English: Paediatric No studies with TESAVEL have been performed in paediatric patients.
Croatian: Pedijatrijska populacija Nisu provedena ispitivanja lijeka TESAVEL u pedijatrijskih bolesnika.
English: TESAVEL contains the active substance sitagliptin which is a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus.
Croatian: TESAVEL sadrži djelatnu tvar sitagliptin, koja pripada skupini lijekova koji se zovu DPP-4 inhibitori (inhibitori dipeptidil-peptidaze 4), koji snižavaju razine šećera u krvi u odraslih bolesnika sa šećernom bolešću tipa 2.
English: No dose adjustment for TESAVEL is necessary for patients with mild or moderate hepatic impairment (Child-Pugh score  9).
Croatian: Nije potrebna prilagodba doze lijeka TESAVEL u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre (Child-Pugh rezultat ≤ 9).
English: When used in combination with metformin and/or a PPAR agonist, the dose of metformin and/or PPAR agonist should be maintained, and TESAVEL administered concomitantly.
Croatian: Kada se uzima u kombinaciji s metforminom i/ili agonistom PPAR, mora se zadržati ista doza metformina i/ili agonista PPAR, uz istodobnu primjenu lijeka TESAVEL.
English: Hypoglycaemia when used in combination with other anti-hyperglycaemic medicinal products In clinical trials of TESAVEL as monotherapy and as part of combination therapy with medicinal products not known to cause hypoglycaemia (i.e. metformin and/or a PPAR agonist), rates of hypoglycaemia reported with sitagliptin were similar to rates in patients taking placebo.
Croatian: Hipoglikemija pri uzimanju u kombinaciji s drugim antihiperglikemijskim lijekovima U kliničkim ispitivanjima lijeka TESAVEL kao monoterapije ili kao dio kombinirane terapije s lijekovima za koje nije poznato da uzrokuju hipoglikemiju (tj. metforminom i/ili agonistom PPAR), stope prijavljenih hipoglikemija u bolesnika koji su uzimali sitagliptin bile su podjednake onoj u bolesnika koji su uzimali placebo.
English: TESAVEL is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors.
Croatian: TESAVEL pripada skupini oralnih antihiperglikemijskih lijekova koji se zovu inhibitori dipeptidil-peptidaze 4 (DPP-4).
English: If a hypersensitivity reaction is suspected, TESAVEL should be discontinued.
Croatian: Pri sumnji na reakciju preosjetljivosti mora se prekinuti uzimanje lijeka TESAVEL.
English: TESAVEL should not be used during breast-feeding.
Croatian: TESAVEL se ne smije uzimati tijekom dojenja.
English: If a dose of TESAVEL is missed, it should be taken as soon as the patient remembers.
Croatian: Propusti li bolesnik dozu lijeka TESAVEL, treba je uzeti čim se sjeti.
English: For patients with severe renal impairment (GFR ≥ 15 to <30 mL/min) or with end-stage renal disease (ESRD) (GFR < 15 mL/min), including those requiring haemodialysis or peritoneal dialysis, the dose of TESAVEL is 25 mg once daily.
Croatian: U bolesnika s teškim oštećenjem funkcije bubrega (GFR ≥ 15 do < 30 ml/min) ili onih u završnoj fazi bubrežne bolesti, (engl. end stage renal disease, ESRD) (GFR < 15 ml/min), uključujući i one kojima je potrebna hemodijaliza ili peritonealna dijaliza, doza lijeka TESAVEL je 25 mg jedanput na dan.
English: For patients with moderate renal impairment (GFR  30 to < 45 mL/min), the dose of TESAVEL is 50 mg once daily.
Croatian: U bolesnika s umjerenim oštećenjem funkcije bubrega (GFR ≥ 30 do < 45 ml/min) doza lijeka TESAVEL je 50 mg jedanput na dan.
English: Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving TESAVEL (see section 4).
Croatian: U bolesnika koji su uzimali lijek TESAVEL prijavljeni su slučajevi upale gušterače (pankreatitis) (pogledajte dio 4.).
English: It is important to stay on the diet and exercise recommended by your doctor while taking TESAVEL.
Croatian: Dok uzimate lijek TESAVEL, važno je da se pridržavate preporuka svog liječnika o dijeti i tjelovježbi.
English: How to take TESAVEL
Croatian: Kako uzimati lijek TESAVEL
English: See TECOS Cardiovascular Safety Study below.
Croatian: Vidjeti odlomak "Ispitivanje kardiovaskularne sigurnosti TECOS"u nastavku.
English: How to store TESAVEL
Croatian: Kako čuvati lijek TESAVEL
English: Musculoskeletal and connective tissue disorders arthralgia
Croatian: Poremećaji mišićno-koštanog sustava i vezivnog tkiva artralgija nepoznata učestalost
English: If bullous pemphigoid is suspected, TESAVEL should be discontinued.
Croatian: Pri sumnji na bulozni pemfigoid treba prekinuti liječenje lijekom TESAVEL.
English: Tel.: +39 06 91393303 addendapharma@legalmail.it
Croatian: Addenda Pharma S.r.l. Tel.: +39 06 91393303 info@addenda.it
English: Tell your doctor if you have or have had: - a disease of the pancreas (such as pancreatitis) - gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood.
Croatian: - Žučne kamence, ovisnost o alkoholu ili vrlo visoke razine trigliceride (vrste masnoća) u Vašoj krvi.
English: After 54 weeks, the mean reduction from baseline in HbA1c was -0.76 % with sitagliptin and -0.64 % with glipizide (PerProtocol Analysis).
Croatian: Nakon 54 tjedna liječenja prosječno sniženje HbA1c u odnosu na početne vrijednosti iznosilo je -0,76% uz sitagliptin te -0,64% uz glipizid (analiza po realiziranom planu ispitivanja).
English: TESAVEL 25 mg tablets Sitagliptin
Croatian: TESAVEL 25 mg tablete sitagliptin
English: EU/1/07/435/001 EU/1/07/435/002 EU/1/07/435/003 EU/1/07/435/004 EU/1/07/435/005 EU/1/07/435/006 EU/1/07/435/019 EU/1/07/435/020
Croatian: EU/1/07/435/003 EU/1/07/435/004 EU/1/07/435/005 EU/1/07/435/006 EU/1/07/435/019 EU/1/07/435/020
English: EU/1/07/435/013 EU/1/07/435/014 EU/1/07/435/015 EU/1/07/435/016 EU/1/07/435/017 EU/1/07/435/018 EU/1/07/435/023 EU/1/07/435/024
Croatian: EU/1/07/435/015 EU/1/07/435/016 EU/1/07/435/017 EU/1/07/435/018 EU/1/07/435/023 EU/1/07/435/024